Transdermal Peptide Tech-Transdermal Complex Peptide-Bio-Transdermal给药技术-Mellgen Biotech

Mellgen (Shenzhen) Biotechnology Co., Ltd.

Reshaping Youth · Locking In Skin AgeGlobal Pioneer in Biological Transdermal Technology

186-9197-8530 / 0755-82926499

Current Location: Home > Transdermal Peptide Tech

Mellgen BiotechDisruptive 3rd-Gen Transdermal Peptide Fusion Tech

Utilizing AI molecular design, synthetic biology foundations, genetic engineering, and fermentation technology to develop next-generation transdermal-enhanced bio-active molecules, realizing the green development and industrialization of featured functional bio-resources such as protein peptides, plant polysaccharides, and microbial fermentation products, greatly enhancing the utilization efficiency of active molecules in skin repair and health care.

22 Years R&D Experience: 22 Years R&D Experience

Through 22 years of dedicated scientific research, we have accumulated profound R&D and application experience in biological transdermal technology, focusing on becoming a highly trusted innovative enterprise in this field.

SCI Journal Publications: SCI Journal Publications

Published over 30 high-quality papers in top international academic journals including Nature and Science, with cumulative impact factors exceeding 200, attracting widespread global academic acclaim.

6 R&D Laboratories: 6 R&D Laboratories

A comprehensive R&D laboratory system comprising 6 major labs: AI Molecular Design, Molecular Cloning Biology, Cell Biology, Synthetic Biology, Bio-Transdermal Delivery, and Skin Efficacy Testing.

Sci-Tech Fund Support: Sci-Tech Fund Support

Multiple R&D projects supported by the National Youth Science Fund, National Postdoctoral Research Fund, USTC Youth Science Fund, and Shenzhen Science & Tech Innovation Fund.

NMPA Filing & Registration: NMPA Filing & Registration

High-quality bio-materials have completed standard safety information and DMF filing with the NMPA. Backed by an advanced AI-driven end-to-end R&D system, we rapidly respond to client demands and deliver mass production.

4 Rare Resource Libraries: 4 Rare Resource Libraries

Equipped with 4 globally scarce proprietary bio-resource repositories: Transdermal Peptide Library, Skin Active Peptide & Protein Library, Microbial Genetic Element Library, and Microbial Strain Library.

22 Years R&D Experience

SCI Journal Publications

6 R&D Laboratories

Sci-Tech Fund Support

NMPA Filing & Registration

4 Rare Resource Libraries

Bio-Transdermal给药平台

Biological transdermal delivery technology is a transdermal peptide molecular technology founded by Prof. Wen Longping's team at USTC，Using peptides as molecular chaperones to solve the worldwide challenge of biomacromolecule transdermal absorption。研究成果发表在世界学术期刊《自然生物技术》，并荣获“中国基础研究十大新闻”，国际Transdermal给药大师 Mark Prausnit 给予充分肯定。

Mellgen Biotech基于Synthetic Biology方法发明了“Transdermal肽融合技术”，Greatly improves the transdermal transport efficiency of macromolecular drugs while significantly reducing costs；First in the world to propose the energy participation in transdermal peptide transport，研究成果发表在药学一区期刊《Molecular Pharmaceutics》杂志。The company possesses proprietary transdermal peptide sequence and plasmid vector libraries。

Transdermal肽的渗透途径

第三代Transdermal Technology

研发生产中心Production strength

Mellgen Biotech · 研发实力

公司占地面积4600平米，拥有Biological Transdermal Technology孵化平台，可开展分子生物学、细胞生物学、发酵与纯化工程、制剂开发及人体功效验证等研发工作。1000 平制药级 GMP 细胞工厂，装载 7 台发酵罐，总装量达 5 吨；2000 平制剂生产平台，含冻干粉剂生产线，乳化生产线。公司具备从上游分子设计、工艺开发和功效验证到下游原料生产以及终端产品生产贯通的上下游产业链。

技术突破，稳定产出高水平学术成果

全球Biological Transdermal Technology的原创团队，汇聚了10多位研发科学家，成员分别来自美国Stanford University、University of Science and Technology of China (USTC)、The University of Hong Kong (HKU)以及South China University of Technology (SCUT)，涵盖教授、博士与博士后。我们对分子结构，分子序列，制备工艺, 科学配方,菌株等技术实施全方位严格保护，形成无法超越的技术壁垒！

应用领域

Mellgen Biotech基于Synthetic Biology方法发明了第3代“Transdermal肽融合技术”；显著提高活性成分Transdermal吸收效率，有效优化应用开发成本（*实验室科研对比数据）；
As a platform technology, biological transdermal tech is widely applicable in biomedicine and medical aesthetics。